



Letter to the Editor

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1


ARTICLE INFO

Editor: Mohandas Narla

Author disclosures

Pramod Mistry: Lead principle investigator in the eliglustat ENGAGE trial and principal investigator in the eliglustat ENCORE trial. Member of the International Collaborative Gaucher Group (ICGG) Gaucher Registry North American Advisory Board. Receives research support from Sanofi Genzyme and honoraria and travel reimbursement from Sanofi Genzyme.

Manisha Balwani: Principal investigator in the eliglustat ENGAGE and ENCORE trials. Member of the ICGG Gaucher Registry North American Advisory Board. Has received honoraria and travel reimbursement from Sanofi Genzyme.

Hagit N. Baris: Principal investigator in the eliglustat ENGAGE trial. Recipient of research grants from Pfizer, Sanofi Genzyme, Shire, of honoraria from Sanofi Genzyme and Shire, of travel grants from Genzyme, Shire, Protalix and Pfizer and advisory board member of Sanofi Genzyme and Shire.

Hadhani Ben Turkia: Principal investigator in the eliglustat ENCORE trial.

T. Andrew Burrow: Principal investigator in the ENCORE trial. Member of the ICGG Gaucher Registry North American Registry Advisory Board. Has received honoraria and travel reimbursement from Sanofi Genzyme, Shire, and Biomarin.

Joel Charrow: Lead principal investigator for the eliglustat EDGE trial. Received consulting fees for participation in advisory boards from Sanofi Genzyme and Shire, and honoraria for speaking engagements from Sanofi Genzyme and Shire, and is an investigator in clinical trials sponsored by Sanofi Genzyme, Shire, BioMarin, and Amicus.

Gerald F. Cox: former employee, Sanofi Genzyme and owner of Sanofi stock and Genzyme CVR.

Sumita Danda: Principal investigator in the eliglustat ENGAGE trial.

Marta Dragosky: Principal investigator in the eliglustat Phase 2 trial. Has received travel reimbursement from Sanofi Genzyme.

Guillermo Drelichman: Principal investigator in the eliglustat ENCORE trial. Has received honoraria and travel reimbursement from Sanofi Genzyme.

Amal El Beshlawy: Principal investigator in the eliglustat ENCORE trial. Has received a research grant from Sanofi Genzyme.

Cristina Fraga: Principal investigator in the eliglustat EDGE trial. Has received honoraria and travel reimbursement from Sanofi Genzyme.

Selena Freisens: Employee of Sanofi Genzyme and holds Sanofi stock.

Sebastian Gaemers: Employee of Sanofi Genzyme and holds Sanofi stock.

Evgueniy Hadjiev: Principal investigator in the eliglustat ENGAGE trial. Has received honoraria and travel reimbursement from Sanofi Genzyme.

Priya Kishnani: Principal investigator in the eliglustat ENCORE trial. Received research/grant support from Sanofi Genzyme, Shire Pharmaceuticals, and Pfizer; and has received consulting fees and honoraria from Sanofi Genzyme, Shire Pharmaceuticals. Member of the ICGG Gaucher Registry Advisory Board for Sanofi Genzyme; Scientific Advisory Board for Shire Pharmaceuticals.

Elena Lukina: Lead principal investigator in the eliglustat Phase 2 trial; principal investigator in the eliglustat ENGAGE, ENCORE, and EDGE trials. Has received honoraria and travel reimbursement from Sanofi Genzyme and Shire.

Pierre Maison-Blanche: Has received honoraria and travel reimbursement from Sanofi Genzyme.

Ana Maria Martins: Principal investigator in the eliglustat ENGAGE and ENCORE trials. Has received research funding resources, lectures fees, support for continuing medical education from Sanofi Genzyme, Alexion, and Biomarin.

Gregory Pastores: Principal investigator in the eliglustat ENGAGE and ENCORE trials. Has received grant/research support from Actelion, Alexion, Amicus/GSK, BioMarin, Sanofi Genzyme, Protalix BioTherapeutics/Pfizer, and Shire.

Milan Petakov: Principal investigator in the eliglustat ENGAGE trial.

M. Judith Peterschmitt: Employee of Sanofi Genzyme and holds Sanofi stock.

Hanna Rosenbaum: Principal investigator in the eliglustat Phase 2 trial. Has received honoraria and travel reimbursement from Sanofi Genzyme. Recipient of research grants from Pfizer and Sanofi Genzyme.

Barry Rosenbloom: Principal investigator in the eliglustat ENCORE trial, member of the ICGG Gaucher Registry North American Advisory Board. Has received honoraria and travel reimbursement from Sanofi Genzyme.

Lisa H. Underhill: Employee of Sanofi Genzyme.

Timothy M. Cox: Lead principal investigator in the eliglustat ENCORE trial. Has received Honoraria, travel reimbursement and grant/research support from Shire Pharmaceuticals and an honorarium from Amicus/GSK.

<https://doi.org/10.1016/j.bcmd.2019.04.003>

Received 5 April 2019; Accepted 6 April 2019

Available online 09 April 2019

1079-9796/ © 2019 Elsevier Inc. All rights reserved.

- Pramod K. Mistry^a, Manisha Balwani^b, Hagit N. Baris^c,
 Hadhami Ben Turkia^d, T. Andrew Burrow^e, Joel Charrow^f,
 Gerald F. Cox^g, Sumita Danda^h, Marta Dragoskyⁱ,
 Guillermo Drelichman^j, Amal El-Beshlawy^k, Cristina Fraga^l,
 Selena Freisens^m, Sebastiaan Gaemers^m, Evgueniy Hadjievⁿ,
 Priya S. Kishnani^o, Elena Lukina^p, Pierre Maison-Blanche^q,
 Ana Maria Martins^r, Gregory Pastores^s, Milan Petakov^t,
 M. Judith Peterschmitt^m, Hanna Rosenbaum^u, Barry Rosenbloom^v,
 Lisa H. Underhill^m, Timothy M. Cox^{w,*}
- ^a Yale University School of Medicine, New Haven, CT, USA
^b Icahn School of Medicine at Mount Sinai, New York, NY, USA
^c The Genetics Institute, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
^d Hôpital La Rabta, Tunis, Tunisia
^e College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
^f Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
^g Editas, Cambridge, MA, USA (formerly Sanofi Genzyme), Cambridge, MA, USA
- ^h Christian Medical College, Vellore, India
ⁱ IMAI-Research, Buenos Aires, Argentina
^j Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina
^k Pediatric Hematology, Cairo University, Egypt
^l HDES Hospital, Ponta Delgada, Açores, Portugal
^m Sanofi Genzyme, Cambridge, MA, USA
ⁿ University Hospital Alexandrovska, Sofia, Bulgaria
^o Duke University School of Medicine, Department of Pediatrics, Durham, NC, USA
^p National Research Center for Hematology, Moscow, Russia
^q Bichat University Hospital, Paris, France
^r Universidade Federal de São Paulo, São Paulo, SP, Brazil
^s New York University School of Medicine, New York, NY, USA
^t Clinical Center of Serbia, University of Belgrade School of Medicine, Belgrade, Serbia
^u Rambam Medical Center, Haifa, Israel
^v Cedars-Sinai, Tower Hematology Oncology, Beverly Hills, CA, USA
^w University of Cambridge, Department of Medicine, Box 157, Level 5, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
 E-mail address: tmc12@medschl.cam.ac.uk (T.M. Cox).

* Corresponding author.